Novel System Snags FDA Approval for Severe Peripheral Arterial Disease
Device designed to prevent amputation in chronic limb-threatening ischemia
Stay updated with breaking news from Daniel Clair. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Device designed to prevent amputation in chronic limb-threatening ischemia
The basis for the approval was the successful results for deep-vein arterialization borne out in the PROMISE II trial.
LimFlow announced today that the FDA approved its LimFlow System for treating chronic limb-threatening ischemia (CLTI).
/PRNewswire/ -- Leading physicians and researchers will present results from 20 clinical trials from Monday, October 30, to Wednesday, November 1, at the...
Data from the PROMISE II study detail the effects of transcatheter arterialization procedures with the LimFlow System for reducing the rate of amputation in people with chronic limb-threatening ischemia.